Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Journal of Clinical Oncology(2021)10.1200/jco.20.02262Source: DataRank Database

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL is a research paper published in Journal of Clinical Oncology (2021). On theSindex it has a DataRank of 6.9. It has been cited 362 times, with 100 citing works in its 1-hop citation network.

N/A

6.9DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access362 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01593696

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 24.09)OA: greenTopics (29)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 13%Citation Network 87%

Base Score Contribution

0.884

From this paper's citation signal

Citation Network Contribution

6.0

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Journal of Clinical Oncology2022360 citations12 referencesContributes 0.491
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma
Nature Medicine202556 citations17 referencesContributes 0.238
Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy
Blood Advances202327 citations16 referencesContributes 0.208
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
The Lancet2021782 citations33 referencesContributes 0.202
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
Blood Cancer Discovery2021183 citations26 referencesContributes 0.201

Authors (14)

Daniel W. Lee ORCID,Bonnie Yates,Constance M. Yuan ORCID,Haneen Shalabi ORCID,Staci Martin ORCID

Live enrichment

PubMed:33764809 PMC:PMC8274806 OpenAlex:https://openalex.org/W3138004978

Intramural NIH HHS

Grant: ZIA BC011823

NCI NIH HHS

Grant: P30 CA124435

Intramural NIH HHS

Grant: ZIA BC011498

FWCI

24.09

Citation Percentile

1.0%

Influential Citations

Citation Trend

2012

2021

2022

2023

2024

2025

2026

green

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8274806

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274806

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8274806

publisherhttps://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02262

journalhttps://doi.org/10.1200/jco.20.02262

Fields of Study

CAR-T cell therapy researchAcute Lymphoblastic Leukemia researchLymphoma Diagnosis and TreatmentMedicine

MeSH Terms

AdolescentAdultChildChild, PreschoolFemaleFollow-Up StudiesHumansMalePrecursor B-Cell Lymphoblastic Leukemia-LymphomaImmunotherapy, AdoptiveYoung Adult

Keywords

FludarabineMedicineCyclophosphamideMinimal residual diseaseCumulative incidenceInternal medicineGastroenterologyRefractory (planetary science)Hematopoietic stem cell transplantationImmunologyLeukemiaCohortTransplantationChemotherapy

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Unrelated cord blood transplantation vs. HLA-matched sibling transplantation for adults with B-cell acute lymphoblastic leukemia in complete remission: superior OS for patients with long-term survival

10.6084/m9.figshare.21303607.v1figshare

10.6084/m9.figshare.21303607figshare

Additional file 4 of CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL

10.6084/m9.figshare.22604312.v1figshare

Additional file 4 of CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL

10.6084/m9.figshare.22604312figshare

Additional file 1 of Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

10.6084/m9.figshare.22625741.v1figshare

Additional file 1 of Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

10.6084/m9.figshare.22625741figshare

Additional file 1 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.25876174.v1figshare

Additional file 1 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.25876174figshare

Additional file 2 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.25876343.v1figshare

Additional file 2 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.25876343figshare

Additional file 1 of The application of HER2 and CD47 CAR-macrophage in ovarian cancer

10.6084/m9.figshare.26619154.v1figshare

Additional file 1 of The application of HER2 and CD47 CAR-macrophage in ovarian cancer

10.6084/m9.figshare.26619154figshare

Additional file 3 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.26723918.v1figshare

Additional file 3 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.26723918figshare

Additional file 4 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.26723921.v1figshare

Additional file 4 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.26723921figshare

Additional file 5 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.26723924figshare

Additional file 5 of Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics

10.6084/m9.figshare.26723924.v1figshare

Additional file 9 of Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

10.6084/m9.figshare.26587881.v1figshare

Additional file 5 of Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

10.6084/m9.figshare.26587869.v1figshare